Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 167 entries
Sorted by: Best Match Show Resources per page
Nomegestrol acetate-17b-estradiol for oral contraception.

Patient preference and adherence

Burke A.
PMID: 23836965
Patient Prefer Adherence. 2013 Jun 27;7:607-19. doi: 10.2147/PPA.S39371. Print 2013.

Oral contraceptives remain a popular method of contraception over 50 years after their introduction. While safe and effective for many women, the failure rate of oral contraception is about 8%. Concerns about the risk of venous thromboembolism continue to...

Cite
Burke A. Nomegestrol acetate-17b-estradiol for oral contraception. Patient Prefer Adherence. 2013;7:607-19doi: 10.2147/PPA.S39371.
Burke, A. (2013). Nomegestrol acetate-17b-estradiol for oral contraception. Patient preference and adherence, 7607-19. https://doi.org/10.2147/PPA.S39371
Burke, Anne. "Nomegestrol acetate-17b-estradiol for oral contraception." Patient preference and adherence vol. 7 (2013): 607-19. doi: https://doi.org/10.2147/PPA.S39371
Burke A. Nomegestrol acetate-17b-estradiol for oral contraception. Patient Prefer Adherence. 2013 Jun 27;7:607-19. doi: 10.2147/PPA.S39371. Print 2013. PMID: 23836965; PMCID: PMC3702550.
Copy Download .nbib Format: NLM
Congenital Adrenal Hyperplasia due to 17-alpha-hydoxylase/17,20-lyase Deficiency Presenting with Hypertension and Pseudohermaphroditism: First Case Report from Oman.

Oman medical journal

Mula-Abed WA, Pambinezhuth FB, Al-Kindi MK, Al-Busaidi NB, Al-Muslahi HN, Al-Lamki MA.
PMID: 24498484
Oman Med J. 2014 Jan;29(1):55-9. doi: 10.5001/omj.2014.12.

This is the first report of congenital adrenal hyperplasia (CAH) due to combined 17α-hydroxylase/17,20 lyase deficiency in an Omani patient who was initially treated for many years as a case of hypertension. CAH is an uncommon disorder that results...

Cite
Mula-Abed WA, Pambinezhuth FB, Al-Kindi MK, et al. Congenital Adrenal Hyperplasia due to 17-alpha-hydoxylase/17,20-lyase Deficiency Presenting with Hypertension and Pseudohermaphroditism: First Case Report from Oman. Oman Med J. 2014;29(1):55-9doi: 10.5001/omj.2014.12.
Mula-Abed, W. A., Pambinezhuth, F. B., Al-Kindi, M. K., Al-Busaidi, N. B., Al-Muslahi, H. N., & Al-Lamki, M. A. (2014). Congenital Adrenal Hyperplasia due to 17-alpha-hydoxylase/17,20-lyase Deficiency Presenting with Hypertension and Pseudohermaphroditism: First Case Report from Oman. Oman medical journal, 29(1), 55-9. https://doi.org/10.5001/omj.2014.12
Mula-Abed, Waad-Allah S, et al. "Congenital Adrenal Hyperplasia due to 17-alpha-hydoxylase/17,20-lyase Deficiency Presenting with Hypertension and Pseudohermaphroditism: First Case Report from Oman." Oman medical journal vol. 29,1 (2014): 55-9. doi: https://doi.org/10.5001/omj.2014.12
Mula-Abed WA, Pambinezhuth FB, Al-Kindi MK, Al-Busaidi NB, Al-Muslahi HN, Al-Lamki MA. Congenital Adrenal Hyperplasia due to 17-alpha-hydoxylase/17,20-lyase Deficiency Presenting with Hypertension and Pseudohermaphroditism: First Case Report from Oman. Oman Med J. 2014 Jan;29(1):55-9. doi: 10.5001/omj.2014.12. PMID: 24498484; PMCID: PMC3910417.
Copy Download .nbib Format: NLM
Estradiol valerate and dienogest: a new approach to oral contraception.

International journal of women's health

Kiley JW, Shulman LP.
PMID: 21892339
Int J Womens Health. 2011;3:281-6. doi: 10.2147/IJWH.S22645. Epub 2011 Aug 18.

Most combination oral contraceptives contain ethinyl estradiol and a progestin. A new and novel oral contraceptive formulation combines estradiol valerate (E2V) with dienogest (DNG) in a four-phase dosing regimen. 17β-estradiol is a naturally-occurring estrogen, and a contraceptive pill containing...

Cite
Kiley JW, Shulman LP. Estradiol valerate and dienogest: a new approach to oral contraception. Int J Womens Health. 2011;3:281-6doi: 10.2147/IJWH.S22645.
Kiley, J. W., & Shulman, L. P. (2011). Estradiol valerate and dienogest: a new approach to oral contraception. International journal of women's health, 3281-6. https://doi.org/10.2147/IJWH.S22645
Kiley, Jessica W, and Shulman, Lee P. "Estradiol valerate and dienogest: a new approach to oral contraception." International journal of women's health vol. 3 (2011): 281-6. doi: https://doi.org/10.2147/IJWH.S22645
Kiley JW, Shulman LP. Estradiol valerate and dienogest: a new approach to oral contraception. Int J Womens Health. 2011;3:281-6. doi: 10.2147/IJWH.S22645. Epub 2011 Aug 18. PMID: 21892339; PMCID: PMC3163658.
Copy Download .nbib Format: NLM
Epidemiological Profile of Drug Overdose Reported in South-East Morocco from 2004 to 2016.

Drugs - real world outcomes

Azekour K, Belamalem S, Soulaymani A, El Houate B, El Bouhali B.
PMID: 30820765
Drugs Real World Outcomes. 2019 Mar;6(1):11-17. doi: 10.1007/s40801-019-0148-2.

BACKGROUND: Drug overdose, either accidental or intentional, is the most common cause of acute poisoning worldwide.OBJECTIVE: The aim of this study was to determine the epidemiological profile of drug poisoning recorded in the south east of Morocco and to...

Cite
Azekour K, Belamalem S, Soulaymani A, et al. Epidemiological Profile of Drug Overdose Reported in South-East Morocco from 2004 to 2016. Drugs Real World Outcomes. 2019;6(1):11-17doi: 10.1007/s40801-019-0148-2.
Azekour, K., Belamalem, S., Soulaymani, A., El Houate, B., & El Bouhali, B. (2019). Epidemiological Profile of Drug Overdose Reported in South-East Morocco from 2004 to 2016. Drugs - real world outcomes, 6(1), 11-17. https://doi.org/10.1007/s40801-019-0148-2
Azekour, Karima, et al. "Epidemiological Profile of Drug Overdose Reported in South-East Morocco from 2004 to 2016." Drugs - real world outcomes vol. 6,1 (2019): 11-17. doi: https://doi.org/10.1007/s40801-019-0148-2
Azekour K, Belamalem S, Soulaymani A, El Houate B, El Bouhali B. Epidemiological Profile of Drug Overdose Reported in South-East Morocco from 2004 to 2016. Drugs Real World Outcomes. 2019 Mar;6(1):11-17. doi: 10.1007/s40801-019-0148-2. PMID: 30820765; PMCID: PMC6423242.
Copy Download .nbib Format: NLM
Cerebral Sinus Venous Thrombosis in a Patient Using Etonogestrel/Ethinyl Estradiol Vaginal Ring.

Cureus

Selim M, Rakhra A, Kassim T, Sen R, Jabbari J, Valenta C.
PMID: 30338179
Cureus. 2018 Aug 05;10(8):e3103. doi: 10.7759/cureus.3103.

A case of 43-year-old female presented to the emergency department (ED) with a new onset grand mal tonic-clonic seizure lasting at least two minutes with post-ictal confusion. Imaging was consistent with cerebral sinus venous thrombosis (CSVT) associated with intracranial...

Cite
Selim M, Rakhra A, Kassim T, et al. Cerebral Sinus Venous Thrombosis in a Patient Using Etonogestrel/Ethinyl Estradiol Vaginal Ring. Cureus. 2018;10(8):e3103doi: 10.7759/cureus.3103.
Selim, M., Rakhra, A., Kassim, T., Sen, R., Jabbari, J., & Valenta, C. (2018). Cerebral Sinus Venous Thrombosis in a Patient Using Etonogestrel/Ethinyl Estradiol Vaginal Ring. Cureus, 10(8), e3103. https://doi.org/10.7759/cureus.3103
Selim, Mohammad, et al. "Cerebral Sinus Venous Thrombosis in a Patient Using Etonogestrel/Ethinyl Estradiol Vaginal Ring." Cureus vol. 10,8 (2018): e3103. doi: https://doi.org/10.7759/cureus.3103
Selim M, Rakhra A, Kassim T, Sen R, Jabbari J, Valenta C. Cerebral Sinus Venous Thrombosis in a Patient Using Etonogestrel/Ethinyl Estradiol Vaginal Ring. Cureus. 2018 Aug 05;10(8):e3103. doi: 10.7759/cureus.3103. PMID: 30338179; PMCID: PMC6175201.
Copy Download .nbib Format: NLM
Contraception for women with epilepsy: counseling, choices, and concerns.

Open access journal of contraception

Reimers A.
PMID: 29386938
Open Access J Contracept. 2016 Apr 19;7:69-76. doi: 10.2147/OAJC.S85541. eCollection 2016.

Approximately 50% of all pregnancies in women with epilepsy (WWE) occur unplanned. This is worrying, given the increased occurrence of obstetrical complications in WWE, including the risk of seizures and their possible consequences for both the mother and the...

Cite
Reimers A. Contraception for women with epilepsy: counseling, choices, and concerns. Open Access J Contracept. 2016;7:69-76doi: 10.2147/OAJC.S85541.
Reimers, A. (2016). Contraception for women with epilepsy: counseling, choices, and concerns. Open access journal of contraception, 769-76. https://doi.org/10.2147/OAJC.S85541
Reimers, Arne. "Contraception for women with epilepsy: counseling, choices, and concerns." Open access journal of contraception vol. 7 (2016): 69-76. doi: https://doi.org/10.2147/OAJC.S85541
Reimers A. Contraception for women with epilepsy: counseling, choices, and concerns. Open Access J Contracept. 2016 Apr 19;7:69-76. doi: 10.2147/OAJC.S85541. eCollection 2016. PMID: 29386938; PMCID: PMC5683160.
Copy Download .nbib Format: NLM
Physical-chemical characteristics and potential use of a novel alginate/zein hydrogel as the sorption phase for polar organic compounds.

Carbohydrate polymers

Castilhos NDB, Sampaio NMFM, da Silva BC, Riegel-Vidotti IC, Grassi MT, Silva BJG.
PMID: 28821098
Carbohydr Polym. 2017 Oct 15;174:507-516. doi: 10.1016/j.carbpol.2017.06.079. Epub 2017 Jul 01.

A novel alginate based hydrogel was successfully prepared and tested for the solid phase microextraction of medium-to-high polarity compounds, when supported in a polypropylene (PP) fiber. Pure alginate when added onto the surface of the PP fiber, resulted in...

Cite
Castilhos NDB, Sampaio NMFM, da Silva BC, et al. Physical-chemical characteristics and potential use of a novel alginate/zein hydrogel as the sorption phase for polar organic compounds. Carbohydr Polym. 2017;174:507-516doi: 10.1016/j.carbpol.2017.06.079.
Castilhos, N. D. B., Sampaio, N. M. F. M., da Silva, B. C., Riegel-Vidotti, I. C., Grassi, M. T., & Silva, B. J. G. (2017). Physical-chemical characteristics and potential use of a novel alginate/zein hydrogel as the sorption phase for polar organic compounds. Carbohydrate polymers, 174507-516. https://doi.org/10.1016/j.carbpol.2017.06.079
Castilhos, Natara D B, et al. "Physical-chemical characteristics and potential use of a novel alginate/zein hydrogel as the sorption phase for polar organic compounds." Carbohydrate polymers vol. 174 (2017): 507-516. doi: https://doi.org/10.1016/j.carbpol.2017.06.079
Castilhos NDB, Sampaio NMFM, da Silva BC, Riegel-Vidotti IC, Grassi MT, Silva BJG. Physical-chemical characteristics and potential use of a novel alginate/zein hydrogel as the sorption phase for polar organic compounds. Carbohydr Polym. 2017 Oct 15;174:507-516. doi: 10.1016/j.carbpol.2017.06.079. Epub 2017 Jul 01. PMID: 28821098.
Copy Download .nbib Format: NLM
High-sensitivity simultaneous liquid chromatography-tandem mass spectrometry assay of ethinyl estradiol and levonorgestrel in human plasma.

Journal of pharmaceutical analysis

Gandhi A, Guttikar S, Trivedi P.
PMID: 29403945
J Pharm Anal. 2015 Oct;5(5):316-326. doi: 10.1016/j.jpha.2015.02.002. Epub 2015 Feb 20.

A sensitive and simultaneous liquid chromatography-tandem mass spectrometry method was developed and validated for quantification of ethinyl estradiol and levonorgestrel. The analytes were extracted with methyl-tert-butyl ether: n-hexane (50:50, v/v) solvent mixture, followed by dansyl derivatization. The chromatographic separation...

Cite
Gandhi A, Guttikar S, Trivedi P. High-sensitivity simultaneous liquid chromatography-tandem mass spectrometry assay of ethinyl estradiol and levonorgestrel in human plasma. J Pharm Anal. 2015;5(5):316-326doi: 10.1016/j.jpha.2015.02.002.
Gandhi, A., Guttikar, S., & Trivedi, P. (2015). High-sensitivity simultaneous liquid chromatography-tandem mass spectrometry assay of ethinyl estradiol and levonorgestrel in human plasma. Journal of pharmaceutical analysis, 5(5), 316-326. https://doi.org/10.1016/j.jpha.2015.02.002
Gandhi, Abhishek, et al. "High-sensitivity simultaneous liquid chromatography-tandem mass spectrometry assay of ethinyl estradiol and levonorgestrel in human plasma." Journal of pharmaceutical analysis vol. 5,5 (2015): 316-326. doi: https://doi.org/10.1016/j.jpha.2015.02.002
Gandhi A, Guttikar S, Trivedi P. High-sensitivity simultaneous liquid chromatography-tandem mass spectrometry assay of ethinyl estradiol and levonorgestrel in human plasma. J Pharm Anal. 2015 Oct;5(5):316-326. doi: 10.1016/j.jpha.2015.02.002. Epub 2015 Feb 20. PMID: 29403945; PMCID: PMC5762240.
Copy Download .nbib Format: NLM
Oral ethinyl estradiol treatment in women with cystic fibrosis is associated with lower bone mineral density.

Journal of clinical & translational endocrinology

Wu M, Hunt WR, Putman MS, Tangpricha V.
PMID: 32257821
J Clin Transl Endocrinol. 2020 Mar 19;20:100223. doi: 10.1016/j.jcte.2020.100223. eCollection 2020 Jun.

OBJECTIVE: The purpose of this study was to determine whether estrogen supplementation primarily from oral contraceptive pills compared to no estrogen supplementation is associated with differences in mean bone mineral density (BMD) measured by DXA in a cross-sectional study...

Cite
Wu M, Hunt WR, Putman MS, et al. Oral ethinyl estradiol treatment in women with cystic fibrosis is associated with lower bone mineral density. J Clin Transl Endocrinol. 2020;20:100223doi: 10.1016/j.jcte.2020.100223.
Wu, M., Hunt, W. R., Putman, M. S., & Tangpricha, V. (2020). Oral ethinyl estradiol treatment in women with cystic fibrosis is associated with lower bone mineral density. Journal of clinical & translational endocrinology, 20100223. https://doi.org/10.1016/j.jcte.2020.100223
Wu, Malinda, et al. "Oral ethinyl estradiol treatment in women with cystic fibrosis is associated with lower bone mineral density." Journal of clinical & translational endocrinology vol. 20 (2020): 100223. doi: https://doi.org/10.1016/j.jcte.2020.100223
Wu M, Hunt WR, Putman MS, Tangpricha V. Oral ethinyl estradiol treatment in women with cystic fibrosis is associated with lower bone mineral density. J Clin Transl Endocrinol. 2020 Mar 19;20:100223. doi: 10.1016/j.jcte.2020.100223. eCollection 2020 Jun. PMID: 32257821; PMCID: PMC7109452.
Copy Download .nbib Format: NLM
Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life.

International journal of clinical pharmacology and therapeutics

Sanga M, Vaughan S, Nangosyah J, Scholz V, Fonseca S.
PMID: 34779392
Int J Clin Pharmacol Ther. 2021 Nov 15; doi: 10.5414/CP204034. Epub 2021 Nov 15.

OBJECTIVE: Evaluate bioequivalence, based on norelgestromin (NGMN) and ethinyl estradiol (EE) plasma concentrations, and adhesion of a transdermal contraceptive patch containing a newly sourced adhesive component (test) at end of shelf life (EOSL) vs. the marketed EVRA patch (reference)...

Cite
Sanga M, Vaughan S, Nangosyah J, et al. Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life. Int J Clin Pharmacol Ther. 2021;doi: 10.5414/CP204034.
Sanga, M., Vaughan, S., Nangosyah, J., Scholz, V., & Fonseca, S. (2021). Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life. International journal of clinical pharmacology and therapeutics, . https://doi.org/10.5414/CP204034
Sanga, Madhu, et al. "Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life." International journal of clinical pharmacology and therapeutics vol. (2021). doi: https://doi.org/10.5414/CP204034
Sanga M, Vaughan S, Nangosyah J, Scholz V, Fonseca S. Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life. Int J Clin Pharmacol Ther. 2021 Nov 15; doi: 10.5414/CP204034. Epub 2021 Nov 15. PMID: 34779392.
Copy Download .nbib Format: NLM
Association between the use of hormonal contraceptives and risk of cholecystectomy in women of reproductive age.

European journal of clinical pharmacology

Khosrow-Khavar F, Sodhi M, Ganjizadeh-Zavareh S, Etminan M.
PMID: 33969435
Eur J Clin Pharmacol. 2021 Oct;77(10):1523-1529. doi: 10.1007/s00228-021-03137-6. Epub 2021 May 10.

PURPOSE: Previous studies have indicated an increased risk of gallbladder disease with hormonal contraceptives although with discordant results. The potential increased risk of gallbladder disease with hormonal contraceptives is concerning given that women are at increased risk of this...

Cite
Khosrow-Khavar F, Sodhi M, Ganjizadeh-Zavareh S, et al. Association between the use of hormonal contraceptives and risk of cholecystectomy in women of reproductive age. Eur J Clin Pharmacol. 2021;77(10):1523-1529doi: 10.1007/s00228-021-03137-6.
Khosrow-Khavar, F., Sodhi, M., Ganjizadeh-Zavareh, S., & Etminan, M. (2021). Association between the use of hormonal contraceptives and risk of cholecystectomy in women of reproductive age. European journal of clinical pharmacology, 77(10), 1523-1529. https://doi.org/10.1007/s00228-021-03137-6
Khosrow-Khavar, Farzin, et al. "Association between the use of hormonal contraceptives and risk of cholecystectomy in women of reproductive age." European journal of clinical pharmacology vol. 77,10 (2021): 1523-1529. doi: https://doi.org/10.1007/s00228-021-03137-6
Khosrow-Khavar F, Sodhi M, Ganjizadeh-Zavareh S, Etminan M. Association between the use of hormonal contraceptives and risk of cholecystectomy in women of reproductive age. Eur J Clin Pharmacol. 2021 Oct;77(10):1523-1529. doi: 10.1007/s00228-021-03137-6. Epub 2021 May 10. PMID: 33969435.
Copy Download .nbib Format: NLM
Comparative evaluation of low-level light therapy and ethinyl estradiol and desogestrel combined oral contraceptive for clinical efficacy and regulation of serum biochemical parameters in primary dysmenorrhoea: a prospective randomised multicentre trial.

Lasers in medical science

Zhu S, Ma X, Ding X, Gan J, Deng Y, Wang Y, Sun A.
PMID: 35028764
Lasers Med Sci. 2022 Jan 14; doi: 10.1007/s10103-021-03490-z. Epub 2022 Jan 14.

We aimed to compare low-level light therapy with oral contraceptive pills for pain relief and serum levels of nitric oxide and prostaglandin E

Cite
Zhu S, Ma X, Ding X, et al. Comparative evaluation of low-level light therapy and ethinyl estradiol and desogestrel combined oral contraceptive for clinical efficacy and regulation of serum biochemical parameters in primary dysmenorrhoea: a prospective randomised multicentre trial. Lasers Med Sci. 2022;doi: 10.1007/s10103-021-03490-z.
Zhu, S., Ma, X., Ding, X., Gan, J., Deng, Y., Wang, Y., & Sun, A. (2022). Comparative evaluation of low-level light therapy and ethinyl estradiol and desogestrel combined oral contraceptive for clinical efficacy and regulation of serum biochemical parameters in primary dysmenorrhoea: a prospective randomised multicentre trial. Lasers in medical science, . https://doi.org/10.1007/s10103-021-03490-z
Zhu, Shiyang, et al. "Comparative evaluation of low-level light therapy and ethinyl estradiol and desogestrel combined oral contraceptive for clinical efficacy and regulation of serum biochemical parameters in primary dysmenorrhoea: a prospective randomised multicentre trial." Lasers in medical science vol. (2022). doi: https://doi.org/10.1007/s10103-021-03490-z
Zhu S, Ma X, Ding X, Gan J, Deng Y, Wang Y, Sun A. Comparative evaluation of low-level light therapy and ethinyl estradiol and desogestrel combined oral contraceptive for clinical efficacy and regulation of serum biochemical parameters in primary dysmenorrhoea: a prospective randomised multicentre trial. Lasers Med Sci. 2022 Jan 14; doi: 10.1007/s10103-021-03490-z. Epub 2022 Jan 14. PMID: 35028764; PMCID: PMC8758216.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 167 entries